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Background: Recent malaria epidemics in KwaZulu-Natal indicate that effective anti-malarial therapy is essential for
malaria control. Although artemether-lumefantrine has been used as first-line treatment for uncomplicated
Plasmodium falciparum malaria in northern KwaZulu-Natal since 2001, its efficacy has not been assessed since 2002.
The objectives of this study were to quantify the proportion of patients treated for uncomplicated P. falciparum
malaria with artemether-lumefantrine who failed treatment after 28 days, and to determine the prevalence of
molecular markers associated with artemether-lumefantrine and chloroquine resistance.
Methods: An observational cohort of 49 symptomatic patients, diagnosed with uncomplicated P. falciparum
malaria by rapid diagnostic test, had blood taken for malaria blood films and P. falciparum DNA polymerase chain
reaction (PCR). Following diagnosis, patients were treated with artemether-lumefantrine (CoartemW) and invited to
return to the health facility after 28 days for repeat blood film and PCR. All PCR P. falciparum positive samples were
analysed for molecular markers of lumefantrine and chloroquine resistance.
Results: Of 49 patients recruited on the basis of a positive rapid diagnostic test, only 16 were confirmed to have P.
falciparum by PCR. At follow-up, 14 were PCR-negative for malaria, one was lost to follow-up and one blood
specimen had insufficient blood for a PCR analysis. All 16 with PCR-confirmed malaria carried a single copy of the
multi-drug resistant (mdr1) gene, and the wild type asparagine allele mdr1 codon 86 (mdr1 86N). Ten of the 16
samples carried the wild type haplotype (CVMNK) at codons 72-76 of the chloroquine resistance transporter gene
(pfcrt); three samples carried the resistant CVIET allele; one carried both the resistant and wild type, and in two
samples the allele could not be analysed.
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Conclusions: The absence of mdr1 gene copy number variation detected in this study suggests lumefantrine
resistance has yet to emerge in KwaZulu-Natal. In addition, data from this investigation implies the possible
re-emergence of chloroquine-sensitive parasites. Results from this study must be viewed with caution, given the
extremely small sample size. A larger study is needed to accurately determine therapeutic efficacy of
artemether-lumefantrine and resistance marker prevalence. The high proportion of rapid diagnostic test
false-positive results requires further investigation.
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KwaZulu-NatalBackground
The World Health Organization (WHO) has recom-
mended that drug efficacy be regularly assessed [1,2].
Failure to detect the emergence of anti-malarial drug re-
sistance, could lead to a drug-resistant malaria epidemic,
which would have major public health and economic
consequences for an area, province and country. The
most recent malaria epidemics in KwaZulu-Natal, one of
three provinces in South Africa with endemic malaria,
were partially attributed to unrecognized resistance to
the anti-malarial therapy being used at the time [3].
Artemether-lumefantrine (AL) has been first-line treat-
ment of uncomplicated Plasmodium falciparum malaria
in northern KwaZulu-Natal since it was introduced in
response to these drug-resistant epidemics in 2001 [4,5].
Studies should be performed to confirm the continued
efficacy of AL, or provide a warning of emerging resistance,
and the need to seek alternative therapy before a malaria
epidemic occurs.Recent history of Plasmodium falciparum anti-malarial
drug resistance in KwaZulu-Natal
Chloroquine resistance was first detected in KwaZulu-Natal
in 1985 [6], and had increased by 1988 [7], leading to
sulphadoxine-pyrimethamine (SP) replacing chloroquine as
the first-line treatment for uncomplicated P. falciparum
malaria in KwaZulu-Natal [4,8,9]. SP remained effective
until 1996 when malaria incidence increased sharply
in KwaZulu-Natal. Between 1996 and 2000 northern
KwaZulu-Natal suffered increasingly severe malaria
epidemics, with more than 40,000 cases reported in
2000 [4,5,10].
Only in 2000, were P. falciparum parasites in the region
shown to have developed at least 61% (and as high as 89%,
excluding those lost to follow-up) resistance to SP in a
clinical efficacy study, rendering the drug ineffective in
northern KwaZulu-Natal [8]. The introduction of AL as
the first-line medication for uncomplicated P. falciparum
malaria, together with the reintroduction of DDT
insecticide for indoor residual house spraying in 2001,
dramatically reduced malaria incidence in the area
[4,5]. It has been estimated that the delay in changingfirst-line treatment for malaria between 1996 and 2000
was responsible for substantial morbidity and mortality, as
well as contributing to the size of the epidemic [3]. Malaria
notifications in KwaZulu-Natal between 1991 and 2001 are
shown (Figure 1).
It has been estimated that in 2000, at the height of the
epidemic, the malaria incidence amongst the exposed
population in northern KwaZulu-Natal was 5,972 per
100,000 [3]. It should be noted that the malaria notification
system became overloaded during these epidemics, and that
the notifications were incomplete. For example during the
year 2000 one clinic, Ndumo Clinic, in northern KwaZulu-
Natal, saw 30,885 cases based on laboratory results, a
50-fold increase compared to 1995 [5], and equivalent to
73% of the total provincial notifications of 42,248 [10].
Artemisinin-based combination therapy (ACT) is advo-
cated for the treatment of uncomplicated P. falciparum
malaria because of the rapid reduction in parasite load
caused by artemisisin or its derivative; the consequent
reduced likelihood of resistance emerging to the partner
drug; the reduction in gametocyte carriage, and rapid
clinical response [11]. ACT is recommended by WHO for
the treatment of P. falciparum malaria [12], and AL is one
of the recommended combinations [2,12]. Studies of AL
therapeutic efficacy in northern KwaZulu-Natal during
2001 and 2002 indicated that AL was effective for treating
uncomplicated malaria in the area [4,13,14]. Since 2002,
there have been no further studies of the continuing thera-
peutic efficacy of AL in KwaZulu-Natal, or South Africa.
The WHO recommends routinely monitoring anti-malarial
resistance at least every three years, and a change in anti-
malarial medicine if the treatment failure proportion is
equal to or greater than 10% by day 28, or the last day of
follow-up, if longer than 28 days [1,12].Pharmacology of artemether-lumefantrine
Artemether-lumefantrine is a combination of two drugs,
artemether and lumefantrine, manufactured in tablet form
as CoartemW by Novartis. Each tablet contains 20 mg
artemether and 120 mg lumefantrine [15]. The two drugs
act in an independent but complementary manner at
different stages of the parasite life cycle [16]. Artemether
Figure 1 Malaria notifications in KwaZulu-Natal from 1991 to 2001. Source: Data 1996-2011 - KwaZulu-Natal Department of Health Malaria
Control Programme; Data 1991-1995 - [3].
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most circulating malaria parasites, while lumefantrine
clears the remainder more slowly [16,17]. The probability
of selecting parasites resistant to the partner drug, lume-
fantrine, is theoretically reduced due to the small parasite
load remaining following activity of artemether [16,17].
Artemether is rapidly absorbed and metabolized, with a
half-life of about two hours, whereas lumefantrine is
absorbed more slowly and has a half-life of 3-4 days in
malaria patients [16,17].
CoartemW is taken as a six-dose oral regimen over
three days. The dosage depends mainly upon the weight
of the patient. The dosage for persons aged 12 years or
more, or younger children weighing 35 kg and above, is
four tablets as a single dose at the time of initial diagnosis,
four tablets after eight hours, and then four tablets
twice daily on each of the following two days [15]. It is
recommended that the tablets are taken with fatty food
or milk to improve absorption [15,17,18].
Choice of follow-up period for anti-malarial efficacy
testing
In the 2009, WHO anti-malarial drug efficacy testing
guide [1], inadequate responses to anti-malarial treat-
ment are classified as: ‘Early Treatment Failure’ in which
there are danger signs or failure to reduce parasitaemia
levels by day 3; ‘Late Clinical Failure’ in which there are
danger signs or parasitaemia and fever occurring
between days 4 and 28, and ‘Late Parasitological Failure’
in which there is parasitaemia without fever between
days 4 and 28. ‘Adequate clinical and parasitological
response’ is the absence of parasitaemia on day 28 (or
day 42 for longer acting drugs), irrespective of axillary
temperature, in patients who did not previously meet
any of the criteria of early treatment failure, late clinicalfailure or late parasitological failure. For drugs with a
half-life of less than seven days, such as artemisinin and
lumefantrine, evaluation of clinical and parasitological
response up to 28 days is recommended [1]. For those
with longer half-lives such as mefloquine (three weeks
[19]) and piperaquine (two to three weeks [20]), a
follow-up of 42 days is recommended [1,12,21].
Although there has been no anecdotal evidence of
resistance to AL in KwaZulu-Natal since its implementa-
tion, artemisinin resistance, characterised by slow clearing
of parasite has been confirmed in South East Asia [22],
and suggested in Kenya [23]. Previous research by Roper
and colleagues demonstrated that SP resistance spread to
southern Africa from East Africa [24]. In neighbouring
Mozambique increase in prevalence of molecular markers
associated with lumefantrine resistance since initial use of
AL suggest the need for continued surveillance for the
emergence of resistance to the drug [25]. The primary
objective of this study was to screen for late AL clinical
failure, the first indication of emerging resistance to AL in
South Africa.
Requiring patients to return a clinic six or seven times
in one month for assessment requires considerable
resources and the risk of drop-out from the study is
high. A single follow-up assessment at 28 days was
therefore chosen which required a patient to return only
once. PCR is recommended by the WHO to distinguish
between P. falciparum recrudescence and re-infection
seven days or more after treatment in areas of both low
to moderate, and high, transmission [1].
Molecular markers of malaria resistance
According to the 2002 WHO report [26], molecular
markers may assist in determining resistance and provide
an early warning of developing drug resistance before it
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been validated for a number of monotherapies, including
chloroquine [27] and lumefantrine [28]. As the genetic
basis for artemisisin resistance is not known, efficacy of
AL is assessed by analyzing molecular markers for lume-
fantrine resistance. Certain molecular markers have been
linked with resistance to lumefantrine, the partner drug in
AL, namely the P. falciparum multidrug resistant (mdr)1
gene copy number [28], and the mdr186N allele [29,30].
Multiple copies of the mdr1 gene has been linked with
lumefantrine resistance in Southeast Asia [28], while
mutations at the codon 86 of the mdr1 gene modulate
lumefantrine efficacy [31].
Storage of blood samples on filter paper for future
testing as new molecular markers become available is
recommended [26].
Ethical issues
The study was approved by the University of KwaZulu-
Natal Biomedical Research Ethics Committee, and by
the Health Research Committee of the KwaZulu-Natal
Department of Health.
Methods
The study population included symptomatic persons pre-
senting to health facilities, diagnosed with uncomplicated
P. falciparum malaria in Umkhanyakude Health District,
northern KwaZulu-Natal, using the P. falciparum malaria
rapid diagnostic test (First Response, malaria antigen P.
falciparum (HRP2) detection rapid card test manufactured
by Premier Medical Corporation Limited, Kachigam,
Daman (UT) 396215, India).
Inclusion criteria
Symptomatic patients aged from five years to 69
years, self presenting to health facilities, diagnosed
with uncomplicated malaria in Umkhanyakude Health
District between January and May 2012, were invited
to participate in the study.
Exclusion criteria
Patients with the following danger signs or symptoms of
severe malaria: unable to drink; vomiting everything; a
convulsion during previous seven days; lethargic or
decreased level of consciousness; unable to stand or sit
[32], were excluded. Pregnant women, patients aged less
than five years and more than 69 years, and patients
treated for malaria during the previous two weeks were
also excluded.
Information provided
At recruitment patients were provided with an information
sheet in English and isiZulu detailing the purpose of the
study, which was also explained verbally. Patient querieswere answered, after which they were invited to provide
written consent.
Investigations
Finger-prick blood spots blotted on to Guthrie 903 filter
paper cards (Munktell GmbH, Barenstien, Germany),
and blood samples were collected from all participants
for molecular analysis and malaria microscopy. The
patient was then asked to return in four weeks for repeat
malaria film microscopy and blood spot collection, with
the offer of ZAR50 (US$5.79) in travelling expenses
upon return. RDT was not performed at follow-up due
to persistence of histidine-rich protein, HRP-2, in
patients for as long as 28 days after parasite clearance
[14,33]. Blood spots taken by nurses were sent to the
investigator at the local hospital. These were then
collected by the Principal Investigator, usually twice per
month, and posted to the researcher performing the
molecular analysis more than 400 km away.
Thick and thin blood films were prepared according to
the National Health Laboratory Service standard operating
procedure for processing specimens for malaria para-
sites [34]. Slides were stained using the Rapid modi-
fied Wright-Giemsa stain (Rapidiff ); thin films being
fixed with methanol before staining. Parasitaemia was
calculated from the percentage of red cells containing
malaria parasites observed in 10 microscope fields
using the 100x lens.
Parasite DNA was extracted from all blood spots
using the QIAamp DNA Mini Kit (QIAGEN, Whitehead
Scientific). The extracted DNA was then subjected qPCR
and nested PCR analysis to confirm the presence of
P. falciparum parasites [35,36].
All samples confirmed as P. falciparum positive by PCR,
were subjected to mutational analysis to detect the prevalence
of molecular markers linked with resistance to lumefantrine,
(mdr1 gene copy number amplification) and chloroquine
(mutations at mdr1 codon 86, [27] and codons 72 to 76 of
the chloroquine resistance transporter (crt) gene) [37]. At
the follow-up visit, the patient was clinically assessed, and
a further finger prick blood sample taken for P. falciparum
PCR and blood film.
Results
A total of 49 patients with a diagnosis of malaria based
on a rapid diagnostic test were enrolled in the study.
Two patients did not have their age recorded. The age
range of the remaining 47 patients was 2 – 69 years;
median 15 years, and mean 21.1 years. The largest group
comprised those less than 10 years of age (Figure 2).
Four patients were less than minimum age of five years
stipulated in the study protocol. Their treatment, however,
was identical to that in the National Treatment Guidelines
[38], and they were included in the analysis.
Figure 2 Age and gender of patients with malaria RDT-positive recruited from Umkhanyakude Health District, January to May 2012
(N=47).
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Only 33% (16/49) patients were confirmed to have P.
falciparum malaria by PCR (Figure 3). Closer inspection
of the RDTs revealed that frequently too much blood
had been used, rendering the test virtually impossible to
interpret. The age range of those confirmed with P.
falciparum was 2 - 40 years with median age 14.5
years and mean 16.8 years. Nearly half (7/16) of those
with PCR-confirmed malaria were aged less than 10
years. Results for the P. falciparum PCR positive
patients are summarized in Table 1.
Presence of fever
Fever (auxiliary temperature ≥37.5°C) was recorded in 64%
(27/42) of all patients who were initially diagnosed with
malaria and 77% (11/14) of the PCR malaria confirmed
cases, while 57% (16/28) of those PCR negative had a fever.
Temperature was not recorded for two malaria PCR
positive patients.Figure 3 Age and gender of patients with P. falciparum malaria confi
January to May 2012 (N=16).Recent travel
Six of the 16 PCR malaria confirmed cases reported having
travelled to Mozambique within the previous month.
Blood films
Due to liaison difficulties with a local laboratory, blood
films were only obtained in 15/49 recruited patients. Of
these, four were PCR-confirmed malaria samples, of which
one was P. falciparum positive by microscopy with a para-
sitaemia of 0.25%. All other 14 blood films were micros-
copy negative for P. falciparum.
Molecular markers
All 16 PCR P. falciparum positive samples collected at
enrolment had a single copy of the mdr1 gene and
carried the wild type asparagine allele at codon 86 of the
mdr1 gene (mdr1 86N) (Table 1). Results for 14 of the
16 samples were crt 72-76 genotyped. Ten samples carried
the wild chloroquine sensitive haplotype (CVMNK), threermed by PCR recruited from Umkhanyakude Health District,
Table 1 Results for patients with PCR confirmed Plasmodium falciparum malaria at enrolment
Age Gender Travel 60 days
prior to illness












40 Female Mozambique 36.5 1 Asparagine
(mdr1 86N)
CVMNK 28 Negative
7 Male Not recorded 39.4 1 asparagine CVMNK and CVIET 191 Negative
32 Female None 36.4 1 asparagine CVIET 168 Insufficient sample
24 Male None 39.3 1 asparagine CVMNK 49 Negative
9 Female Not recorded Not
recorded
1 asparagine CVMNK 29 Negative
31 Male Mozambique 38.3 1 asparagine CVMNK 32 Negative
8 Female None 36.7 1 asparagine CVIET 29 Negative
15 Male Mozambique 38.0 1 asparagine CVIET 106 Negative
20 Male Mozambique 41.0 1 asparagine CVMNK 127 Negative
37 Female Not recorded 38.7 1 asparagine CVMNK 86 Negative
6 Female None 39.0 1 asparagine CVMNK 28 Negative
2 Female Mozambique Not
recorded
1 asparagine CVMNK NA Lost to follow-up;
returned to
Mozambique
17 Male None 38.2 1 asparagine CVMNK 69 Negative
14 Female None 38.0 1 asparagine CVMNK 92 Negative
4 Female Mozambique 38.0 1 asparagine CVMNK 59 Negative
3 Male Not recorded 38.0 1 asparagine CVMNK 57 Negative
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chloroquine treatment failure, while one carried both wild
and mutant alleles. Two samples proved inadequate for crt
genotyping.
Follow-up
Only 14% (7/49) of the patients returned for follow-up, of
which six were P. falciparum PCR positive at enrolment.
Malaria control personnel tracked down and obtained
blood specimens for follow-up PCR from a further nine
non-returning PCR-confirmed patients, at varying intervals
from four weeks following recruitment. Of the initial PCR
positive cohort, 14 were found to be negative at follow up,
one sample contained insufficient blood for testing and
one patient was lost to follow-up.
Discussion
The primary aim of this study was to assess the therapeutic
efficacy of AL, the current first-line treatment of uncompli-
cated P. falciparum malaria in northern KwaZulu-Natal.
The study was hampered by a scarcity of diagnosed malaria
cases. Of 49 patients enrolled in the study on the basis of a
positive P. falciparum rapid diagnostic test, only 16 were
subsequently confirmed to have P. falciparum malaria by
PCR analysis.
Amplification of mdr1 gene copy number associated
with lumefantrine resistance in South East Asia was notdetected in this study [39]. This result confirms the
research findings in neighbouring Mozambique [25],
where no variation in mdr1 copy number was observed
following two years of AL deployment, and supports the
hypothesis that mdr1 amplification is rare in Africa [31].
The mdr1N86Y mutation associated with chloroquine
resistance [27] was completely absent in this study. This
finding together with the high prevalence of the crt 72-76
wild type haplotype (CVMNK) in the study area suggests
AL deployment removed chloroquine drug pressure,
allowing chloroquine sensitive parasites to re-emerge as
seen in Malawi [40] and Mozambique [25]. This return of
parasite sensitivity to chloroquine could result in the re-
introduction of chloroquine in combination with a partner
drug as an anti-malarial.
All follow-up samples were PCR negative for P. falcip-
arum, implying sustained AL efficacy, 11 years after it was
initially rolled out in KwaZulu-Natal. On a cautionary note,
the high mdr186N allele prevalence is a cause for some
concern. It has been suggested that increases in mdr186N
prevalence is the first step towards lumefantrine tolerance
[30]. Sustained lumefantrine drug pressure is probably
driving the selection of the mdr186N allele in KwaZulu-
Natal. In contrast, the removal of chloroquine drug
pressure probably selected for this allele in Mozambique
[25]. Given the wide use of AL in southern Africa and the
high prevalence of resistance markers associated with
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and lumefantrine resistance markers is recommended to
ensure effective first-line treatments are available.
Positive study outcomes
Despite the extremely small sample, some valuable data
was produced by this study.
Blood spots for molecular analysis
In a low malaria-incidence setting, blood spot samples
proved to be a good a source for molecular analysis.
Collection of the filter paper samples was relatively easy
and inexpensive. Once collected and correctly stored the
samples were resilient to delays in collection and trans-
port. PCR is capable of detecting malaria parasites at a
density of four parasites per microlitre, whereas thick
film microscopy is only reliable at a density of 500
parasites per microlitre, meaning PCR is more than 100
times more sensitive than microscopy for the diagnosis of
malaria parasitaemia [41,42]. PCR also has a specificity of
nearly 100% [43].
Monitoring molecular markers of drug resistance,
while a less rigorous method of assessing drug efficacy
than in vivo sensitivity studies, is much less expensive
and time consuming, and is a reasonable method of
surveillance for emerging drug resistance [25]. The
WHO recommends that in countries with very low
levels of transmission, such as South Africa, studies of
molecular markers of resistance should be conducted
every year [1]. Molecular markers in 10 of the 14 available
blood specimens indicated sensitivity to chloroquine,
suggesting that chloroquine resistance may have decreased
following removal of the selection pressure from using
chloroquine as first line therapy. Similar findings have been
demonstrated in neighbouring Mozambique and been
attributed to the withdrawal of chloroquine [25].
Study limitations
Enrolment procedure and administration
The incidence of malaria in the study area remained low
during the study period and cases were geographically
scattered, presenting to several different clinics and
hospitals in Umkhanyakude District. Management and
control of the patient records and specimens was
difficult. The cooperation of healthcare workers from
several health facilities was required and consistency of
the enrolment procedure was difficult to achieve. Blood
was sent by clinic nurses to the local hospital laboratory
who declined to perform blood films on many patients.
Of the 49 recruited patients only 16 were PCR
confirmed malaria. The high proportion of false positive
RDT results was probably mainly due to incorrect use of
the test, indicating a lack of familiarity, and the need for
more training. It is possible that false positive RDTresults have erroneously inflated the notified malaria
cases in the district for some time, and is deserving of
further investigation.
Sample size
The study aimed to obtain a sample size of 50, which is
the minimum recommended by the WHO regardless of
rates of failure anticipated, in order to be representative
[1]. However, this study could only include the malaria
cases available. In an area which suffered severe malaria
epidemics within the past 12 years, partly attributable to
a lack of parasite resistance data required for upgrading
antimalarial treatment policy [3], it is important to
undertake regular drug resistance monitoring, or risk
repeating the mistakes of the past. The last published
malaria resistance studies in KwaZulu-Natal took place
in 2002 [4,14], and the data in this study could be used
to inform a larger study.
Follow-up
Despite the financial incentive offered to recompense for
travelling expenses, most patients had to be tracked
down by malaria control personnel at varying time intervals
after treatment.
Use of single follow-up visit
Use of a single follow-up visit on day 28, rather than
follow-up visits on days 1,2,3,7,14 and 28, as recom-
mended by the WHO [1,26,32], meant that in the event
of persistence of P. falciparum parasitaemia by day 28, it
would not be possible to distinguish between early treat-
ment failure, late clinical failure, and late parasitological
failure. The finding of persistence of parasitaemia by day
28 would provide a motivation for a further study
following the WHO protocol [1] to distinguish the
degree of resistance. However, as already mentioned,
persuading patients to return for six follow-up visits is
not easy, evidenced by the difficulty faced in this study of
obtaining even a single follow-up from patients. The single
28 day follow-up should detect most clinical and treatment
failures, and seems particularly suitable for screening for
late clinical failure and late parasitological failure.
Conclusions
Determining drug efficacy, particularly as malaria trans-
mission approaches zero, is critical, as the last remaining
parasites are most likely the most resistant [44]. Since
therapeutic efficacy of AL in KwaZulu-Natal had not
been assessed recently, this study attempted to address
the issue. Unfortunately the extremely low incidence of
malaria in northern KwaZulu-Natal impacted negatively
on patient recruitment. As drug efficacy data is essential
to inform policy, particularly as South Africa embarks
on an elimination agenda [45], every attempt to obtain
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options include larger studies across multiple sites, and
the follow-up of all malaria cases at 28 days with annual
molecular marker studies [1].
Although 49 patients were recruited into the study based
on RDT results, only 16 were confirmed falciparum
positive by PCR. Preliminary investigations appear to
indicate that incorrect use of RDT was the principal reason
for the high proportion of false-positive results. Since de-
finitive diagnosis is a fundamental tenant of the elimination
agenda, further investigation into the cause of the
false-positive RDT results is indicated, and corrective
measures put in place to prevent misdiagnosis.
Despite the small sample size, all samples were malaria
negative at Day 28, or longer, suggesting sustained AL
efficacy in KwaZulu-Natal. Support for this is provided by
the absence of mdr1 copy number amplification found in
this study. However rigorous regular lumefantrine resist-
ance monitoring is recommended given the high preva-
lence of the mdr186N allele associated with lumefantrine
tolerance and widespread use of AL in southern Africa.
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